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Abstract
Background: Novel therapies for men with castration-resistant prostate cancer (CRPC)
are needed, particularly for cancers not driven by androgen receptor (AR) activation.
Objectives: To identify molecular subgroups of PC bone metastases of relevance for
therapy.
Design, setting, and participants: Fresh-frozen bone metastasis samples from men with
CRPC (n = 40), treatment-naı¨ve PC (n = 8), or other malignancies (n = 12) were charac-
terized using whole-genome expression proﬁling, multivariate principal component
analysis (PCA), and functional enrichment analysis. Expression proﬁles were veriﬁed by
reverse transcription–polymerase chain reaction (RT-PCR) in an extended set of bone
metastases (n = 77) and compared to levels in malignant and adjacent benign prostate
tissue from patients with localized disease (n = 12). Selected proteins were evaluated
using immunohistochemistry. A cohort of PC patients (n = 284) diagnosed at trans-
urethral resection with long follow-up was used for prognostic evaluation.
Results and limitations: The majority of CRPC bone metastases (80%) was deﬁned as AR-
driven based on PCA analysis and high expression of the AR, AR co-regulators (FOXA1,
HOXB13), and AR-regulated genes (KLK2, KLK3, NKX3.1, STEAP2, TMPRSS2); 20% were
non–AR-driven. Functional enrichment analysis indicated high metabolic activity and
low immune responses in AR-driven metastases. Accordingly, inﬁltration of CD3+ and
CD68+ cells was lower in AR-driven than in non–AR-driven metastases, and tumor cell
HLA class I ABC immunoreactivity was inversely correlated with nuclear AR immuno-
reactivity. RT-PCR analysis showed low MHC class I expression (HLA-A, TAP1, and PSMB9
mRNA) in PC bone metastases compared to benign and malignant prostate tissue and
bone metastases of other origins. In primary PC, low HLA class I ABC immunoreactivity
was associated with high Gleason score, bone metastasis, and short cancer-speciﬁc
survival. Limitations include the limited number of patients studied and the single
metastasis sample studied per patient.
Conclusions: Most CRPC bone metastases show high AR and metabolic activities and low
immune responses. A subgroup instead shows low AR and metabolic activities, but highTarimmune responses. * Corresponding author. D
Sweden. Tel. +46 90 78537
E-mail address: pernilla.wi
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Patient summary: We studied heterogeneities at a molecular level in bone metastasis
samples obtained from men with castration-resistant prostate cancer. We found differ-
ences of possible importance for therapy selection in individual patients.
# 2016 European Association of Urology. Published by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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The growth of normal and malignant prostate tissue is
regulated by androgens through activation of the androgen
receptor (AR) in both epithelial and stromal cells, and
androgen deprivation therapy (ADT) is standard treatment
for patients with advanced prostate cancer (PC). However,
after an initial period of reduced symptoms and tumor
growth, relapse occurs and the PC becomes castration
resistant (CRPC). Several mechanisms behind CRPC have
been described, including AR amplification, AR mutations,
expression of constitutively active AR variants, and intra-
crine steroid synthesis, as well as AR bypass mechanisms
[1]. It has been shown that several new drugs prolong
survival and increase quality of life for men with CRPC,
including novel AR antagonists, cytostatic drugs, radio-
isotopes, steroidogenesis inhibitors, immunotherapies, and
therapies targeting the tumor microenvironment [2]. Thus,
there is a need for biomarkers that can guide CRPC therapy
selection. Moreover, the fatal outcome for patients with
CRPC highlights the necessity for further therapeutic
developments, particularly for patients characterized by
low AR activity and for whom no targeting therapy
currently exists.
We previously identified heterogeneous gene expression
patterns of clinical relevance in metastatic CRPC samples,
and found that high levels of the constitutively active AR
variant 7 (AR-V7) were associated with particularly poor
prognosis [3]. Antonarakis and co-workers showed that
detectable levels of AR-V7 in circulating tumors cells are
predictive of poor response to AR-targeted therapies [4]. We
also found a heterogeneous expression pattern for the
steroidogenic enzyme AKR1C3 in clinical samples of CRPC
metastases [5], and the relevance of AKR1C3 as a predictive
marker for therapy response to the steroidogenesis inhibi-
tor abiraterone is currently under evaluation.
The aim of this study was to further characterize gene
expression in bone metastases from men with CRPC to
identify subgroups of relevance for therapy choice.
2. Patients and methods
2.1. Patients
Fresh-frozen bone metastasis samples were obtained from a series of
men with PC (n = 65) or other malignancies (n = 14) who underwent
surgery for metastatic spinal cord compression at Umea˚ University
Hospital between 2003 and 2013. The PC patient series has been
described before [3,5,6] and the clinical characteristics are summarized
in Table 1. Formalin-ﬁxed, parafﬁn-embedded (FFPE) metastasis
samples were available for 41 of the 54 CRPC patients in Table 1 and
matched diagnostic prostate biopsies were available in 29 cases,Please cite this article in press as: Ylitalo EB, et al. Subgroups of 
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the metastasis biopsy. The study also included 12 separate men who
were treated with radical prostatectomy at Umea˚ University Hospital
between 2005 and 2006; the median age for these men was 61 yr (IQR
57–67) and median prostate-speciﬁc antigen (PSA) was 11 ng/ml (IQR
5.3–18 ng/ml). Clinical local stage was T2 (n = 3) or T3 (n = 9) and
Gleason score (GS) was 7 (n = 10) or 8 (n = 2).
Tissue microarrays (TMAs) were previously constructed from
samples taken during transurethral resection of the prostate (TURP)
performed between 1975 and 1991 as previously described [7]. Gleason
score was reevaluated by one pathologist (L.E.) and TMAs were
constructed containing ﬁve to eight samples of tumor tissue and four
samples of nonmalignant tissue from each patient. For this study, TMAs
from 284 patients had tissue available for analysis (Supplementary
Table 1). The patients had not received cancer therapy before TURP and,
according to the therapy traditions in Sweden at that time, the majority
(n = 202) were managed via watchful waiting.
The study was approved by the local ethics review board of Umea˚
University (Dnr 03-185, 2010-240-32, and 02-283).
2.2. Tissue preparation
Bone metastasis samples were instantly fresh-frozen in liquid nitrogen
or placed in 4% buffered formalin. Fixed samples were decalciﬁed in
formic acid before being embedded in parafﬁn. Fresh radical prostatec-
tomy specimens were received at the pathology department immedi-
ately after surgery and cut in 0.5-cm-thick slices before ﬁxation. From
these slices, 20 samples were taken using a 0.5-cm skin punch and frozen
in liquid nitrogen within 30 min after surgery. The prostate slices were
formalin-ﬁxed, embedded in parafﬁn, cut in 5 mm-thick sections, whole-
mounted, and stained with hematoxylin-eosin. Tissue sample composi-
tion (nonmalignant or malignant) was determined according to location
in the whole-mount sections.
2.3. RNA extraction
Representative areas of fresh-frozen bone metastasis samples and of
malignant and nonmalignant prostate tissue (obtained in pairs from the
same patient) were cryosectioned into extraction tubes and RNA was
isolated using the Trizol (Invitrogen, Stockholm, Sweden) or AllPrep
(Qiagen, Stockholm, Sweden) protocol. The percentage of tumor cells in
the samples was determined by examination of parallel sections stained
with hematoxylin-eosin, and varied between 50% and 90%. The RNA
concentrations were quantiﬁed by absorbance measurements using a
spectrophotometer (ND-1000; NanoDrop Technologies, Wilmington, DE,
USA). The RNA quality was analyzed on a 2100 Bioanalyzer (Agilent
Technologies, Santa Clara, CA, USA) and veriﬁed to have a RNA integrity
number 6.
2.4. Whole-genome expression profiling
For each sample, 300 ng of total RNA was ampliﬁed using an Illumina
TotalPrep RNA ampliﬁcation kit (Ambion, Austin, TX, USA) according to
the manufacturer’s protocol. A total of 750 ng of cRNA from each sample
was hybridized to HumanHT-12 v4 Expression BeadChips, including
more than 47 000 probes covering over 31 000 annotated genes,Castration-resistant Prostate Cancer Bone Metastases Deﬁned
vity and Immune Response. Eur Urol (2016), http://dx.doi.org/
Table 1 – Clinical characteristics for patients with prostate cancer or other malignancies who underwent surgery for metastatic spinal cord
compression
Prostate cancer Other malignancies b
Castration-resistant a Not treated Not treated
Patients (n) 54 11 14
Age at diagnosis (yr) 69 (63-74) 76 (64-82) 67 (61-79)
Age at metastasis surgery (yr) 72 (67-79) 76 (64-82) 67 (61-79)
Serum PSA at diagnosis (ng/ml) 72 (36-530) 690 (82-2500) –
Serum PSA at metastasis surgery (ng/ml) 290 (85-780) 690 (82-2500) –
Gleason score at diagnosis –
6 4 (7.4) 1 (9.1)
7 19 (35) 1 (9.1)
8–10 20 (37) 1 (9.1)
Not available 11 (20) 8 (73)
Bicalutamide before surgery – –
Yes 24 (44)
No 30 (56)
Chemotherapy before surgery c – –
Yes 9 (17)
No 45 (83)
Radiation before surgery d – –
Yes 8 (15)
No 46 (85)
Follow-up after metastasis surgery (mo) 5.9 (2.0-15) 37 (24-72) 7.0 (3.6-16)
Data are presented as median (25th–75th percentile) for continuous variables and as number (precentage) for categorical variables. PSA = prostate-speciﬁc
antigen.
a Castration-resistant patients had disease progression after long-term androgen deprivation therapy including surgical ablation, luteinizing hormone–releasing
hormone/GNRH agonist therapy, and therapy with anti-androgens (bicalutamide).
b Other malignancies included kidney (n = 3), colorectal (n = 2), lung (n = 1), liver (n = 1), unknown adenocarcinoma (n = 3), myeloma (n = 2), lymphoma (n = 1),
and sarcoma (n = 1).
c Chemotherapy included taxotere in six cases, estramustine in two cases, and taxotere, carboplatin, and etoposide in one case.
d Radiation towards operation site.
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a HiScan system (Illumina, San Diego, CA, USA) and analysis of array data
was performed using GenomeStudio software (version 2011.1, Illumina).
Samples were normalized by the cubic spline algorithm, and probes with
all signals lower than two times the mean background level were
excluded, leaving 21 675 probes for further analysis.
2.5. Multivariate modeling and univariate analysis
Principal component analysis (PCA), an unsupervised projection method,
was used to create an overview of the variation in data and to detect
clusters and trends among metastasis samples and expressed genes
[8]. Data were mean-centered and scaled to unit variance before
analysis. Models were validated via sevenfold cross-validation. Multi-
variate statistical analyses were performed in SIMCA version 14.0 (MKS
Umetrics AB, Umea˚, Sweden).
Univariate analysis was applied to compare subgroups identiﬁed by
PCA with respect to differences in gene expression and clinical
characteristics. Groups were compared using the Mann-Whitney U-test
for continuous variables and the x2 for categorical variables. Univariate
statistical analyses were performed using SPSS 23.0 software (SPSS,
Chicago, IL, USA).
2.6. Functional enrichment analysis
Functional enrichment analysis was generated via Ingenuity Pathway
Analysis (IPA; www.qiagen.com/ingenuity). IPA core analysis was used to
identify altered canonical pathways. The signiﬁcance of associations
between lists of differently expressed genes and canonical pathways were
assessed using (1) the ratio of differentially expressed genes (molecules)
that map to a speciﬁc pathway, given in relation to the total number ofPlease cite this article in press as: Ylitalo EB, et al. Subgroups of C
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determine the probability that the relationship between the molecules in
the data set and the canonical pathway is explained by chance.
Upstream analysis was used to identify regulators with a probability
of being responsible for the changes in gene expression observed, by
calculating an overlap p value with Fisher’s exact test and an activation
z-score. Details of the IPA core analysis can be obtained at http://pages.
ingenuity.com/IngenuityDownstreamEffectsAnalysisinIPAWhitepaper.
html. Both upregulated and downregulated identiﬁers were submitted as
parameters for the analysis. IPA core analysis default settings were used,
but limited to the human knowledge base.
2.7. Real-time RT-PCR
Samples of 200 ng of total RNA were reversed transcribed using a
Superscript VILO cDNA synthesis kit (Invitrogen, Stockholm, Sweden) in a
total volume of 10 ml. Subsequent qRT-PCR analysis was performed using
TaqMan assays for quantiﬁcation of HLA-A, TAP1, and PSMB9 mRNA levels
(Hs01058806_g1, Hs00388675_m1, and Hs00160610_m1; Life Technol-
ogies, Stockholm, Sweden) on an ABI Prism 7900HT sequence detection
system according to the manufacturers’ protocols. Each sample was run in
duplicate and adjusted for the corresponding RPL13A mRNA level
(Hs01578912_m1, Life Technologies) using the ddCt method. Statistical
differences in mRNA levels between groups were identiﬁed using the
Kruskal-Wallis test followed by the Mann-Whitney U-test. Paired samples
were compared using the Wilcoxon signed-rank test.
2.8. Immunohistochemistry
Tissue sections were deparafﬁnized in xylene and rehydrated in a
graded ethanol series. Immunohistochemistry was performed using anastration-resistant Prostate Cancer Bone Metastases Deﬁned
vity and Immune Response. Eur Urol (2016), http://dx.doi.org/
Fig. 1 – Principal component analysis of 2 1675 assigned gene products in 60 bone metastases samples. (A) Score plot for the first principal component.
Each dot corresponds to one metastasis sample collected from untreated prostate cancer (PC) patients (orange), castration-resistant prostate cancer
(CRPC) patients (beige), and patients with other malignancies (yellow). Samples cluster according to their relative gene expression. (B) Loading plot
showing gene probes responsible for the clustering of samples. Gene probes with positive loading values (p) are expressed at high levels in samples
with positive score values (t) and vice versa. Black circles denote the gene probes for AR, FOXA1, HOXB13, KLK3, KLK2, NKX3.1, STEAP2, and TMPRSS2.
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technique on an automatic Ventana Benchmark Ultra system according
to the manufacturer’s protocol (Roche Diagnostics, Basel, Switzerland),
with primary antibodies for CD3 (1:50, NCL-L-CD3-565; Novocastra,
Newcastle upon Tyne, UK), CD68 (1:2000, M0814; Dako, Glostrup,
Denmark), HLA class I ABC (1:200, ab70328; Abcam, Cambridge, UK), and
FOXA1 (1:200, ab23738; Abcam). The AR was detected after antigen
retrieval in Tris/EDTA (pH 9) with anti-AR (1:150, MUC256-UCE;
Biogenex, Fremont, CA, USA) and an IPﬂx system (Biocare Medical,
Concord, CA, USA) using a Mach3 mouse kit with DAB as chromogen. For
double staining, HLA ABC was detected with Ap RED as chromogen
following AR detection after incubation of sections for 5 min in
denaturation buffer (DNS001H; Biocare Medical). The volume density
of CD68+ cells was determined using a square lattice mounted in the
eyepiece of a light microscope and counting cross-sections falling on
stained cells or reference tissue, and expressed as the average density per
tissue after evaluation of at least ten randomly selected ﬁelds.
Metastasis-inﬁltrating CD3+ cells were less abundant than CD68+ cells
and were therefore evaluated as the number of positive cells in the total
stained tumor area using a Pannoramic 250 FLASH scanner and
Pannoramic viewer 1.15.2 software (3DHISTECH, Budapest, Hungary).
HLA class I ABC staining intensity was scored as negative (0), weak (1),
moderate (2), or intense (3), and the most common score per sample/
TMA core was recorded. For survival analysis, each patient was
represented by the less stained TMA core (median and maximum
intensities were evaluated, with similar results; data not shown).
Nuclear AR immunoreactivity in tumor cells was scored according to
intensity (0 = negative, 1 = weak, 2 = moderate, 3 = intense staining) and
fraction of cells stained (1 = 1–25%, 2 = 26–50%, 3 = 51–75%, 4 = 76–
100%). A total score (ranging from 0 to 12) was obtained by multiplying
the staining intensity and fraction scores, as previously described
[6]. When comparing immunoreactivity between two groups, the Mann-
Whitney U-test and x2 test were used for continuous and categorical
variables, respectively. Survival analysis was performed using the
Kaplan-Meier method, with death from PC as events and death from
other causes as censored events. Correlations between variables were
analyzed using the Spearman rank test.
3. Results
3.1. Whole-genome expression analysis identifies CRPC
subgroups according to AR activity
A set of fresh-frozen bone metastases from CRPC patients
(n = 40) was characterized and compared to bone metastasesPlease cite this article in press as: Ylitalo EB, et al. Subgroups of 
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patients with other primary malignancies using whole-
genome expression profiling and multivariate PCA. The PCA
model resulting from analysis of 21 675 gene probe signals
included nine significant principal components explaining
45% of the total variation in the expression data. The first
component describing the largest variation in the data
(R2X=11%, Q2=7%), and thus the most prominent subgroups,
was selected for further investigation. It is evident in
Figure 1A that the majority of the CRPC bone metastasis
samples cluster close to the untreated PC metastases, while
some CRPC samples cluster closer to metastases of other
malignancies. According to the score values for the first
principal component t1 in Figure 1A, the CRPC samples were
divided into two groups; samples with positive scores
showing high transcript levels of the AR, the AR co-
regulators FOXA1 and HOXB13, and androgen-regulated
genes such as KLK2, KLK3, NKX3.1, STEAP2, and TMPRSS2; and
samples with negative scores showing low levels of these
gene transcripts (Fig. 1B). Univariate analysis of differentially
expressed genes identified the AR and many AR-regulating
and/or AR-regulated gene transcripts among the top genes
with positive fold changes in samples with positive
compared to negative PCA scores (Supplementary
Table 2). On the basis of these findings, the 32 CRPC samples
with positive PCA scores (80%) were defined as AR-driven
and the eight CRPC samples with negative PCA scores (20%)
as non–AR-driven. Notably, patients with AR-driven CRPC
metastases had higher serum PSA levels than patients
with non–AR-driven metastases at the time of metastasis
surgery (and borderline higher PSA at diagnosis). No obvious
association with previous treatments, presence of soft
tissue metastasis, or cancer-specific survival after metastasis
surgery was found (Supplementary Table 3).
3.2. Functional differences between AR-driven and non–AR-
driven CRPC bone metastases
To examine functional differences between AR-driven and
non–AR-driven CRPC samples, the list of differently
expressed genes (fold change   1.5 and p P0.01,
Supplementary Table 2) was imported into the QiagenCastration-resistant Prostate Cancer Bone Metastases Deﬁned
vity and Immune Response. Eur Urol (2016), http://dx.doi.org/
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canonical pathways and identification of upstream regulators.
According to analysis of 617 upregulated and 906 down-
regulated gene transcripts, AR-driven CRPC metastases had
higher metabolic activity for biosynthesis of cholesterol,
pyrimidines, and spermine and degradation of fatty acids
and amino acids when compared to non–AR-driven samples
(Table 2). Among the downregulated canonical pathways in AR-
driven metastases, the cellular immune response was the most
obvious (Table 2). Upstream regulators predicted as responsible
for the differential expression observed between AR-driven and
non–AR-driven CRPC bone metastases are listed in Supple-
mentary Table 4. AR, SPDEF, and FOXA1 were among the top
activated genes that also showed increased mRNA levels in AR-
driven metastases, while several immune regulating genes
such as TGFB1, INFG, and other cytokines were predicted to be
inhibited, and some (CCL5, ETV5, PLAUR, and IFNAR2) also
showed reduced mRNA levels (Supplementary Table 4).
The predicted difference in cellular immune response
was verified by immunohistochemical analysis of CD3+
and CD68+ cells in CRPC bone metastases in FFPE
tissue available, which revealed a significantly higher
volume density of CD68+ monocytes and borderline higher
frequency of CD3+ infiltrating lymphocytes in non–
AR-driven compared to AR-driven bone metastases
(Figure 2A–D). Gene expression data indicated higher
levels of CD3+ T cells, and specifically of CD8+ effectorFig. 2 – Immunohistochemical analysis demonstrating (A) significantly higher 
of CD3+ immune cells in non–AR-driven (n = 8) compared to AR-driven (n = 26)
representative (C) CD68 and (D) CD3 staining of a non–AR-driven metastasis sa
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to AR-driven metastases (Supplementary Fig. 1A–C). This
was accompanied by increased levels of the inhibitory T
cell receptors CTLA4 and PDCD1 and lower levels of the
proinflammatory Th1 transcription factor TBX21 (Supple-
mentary Fig. 1D–F), while levels of the stimulatory T-cell
receptors ICOS and CD28 and the anti-inflammatory
Th2 transcription factor GATA did not differ between
non–AR-driven and AR-driven metastases (data not
shown). We did not detect mRNA for the regulatory T
cell (Treg) transcription factor FOXP3. Non–AR-driven
cases had higher levels of CD68, CD163, and S100A9 mRNA
(Supplementary Fig. 1G–I) but not NOS2 mRNA (data not
shown), indicating metastasis infiltration of tumor-pro-
moting M2 macrophages and myeloid-derived suppressor
cells (MDSCs).
The downregulated antigen presentation observed in
AR-driven CRPC bone metastases (Table 2 and Supplemen-
tary Fig. 2) possibly contributed to the low immune-cell
infiltration, and this pathway was therefore selected for
further examination.
3.3. Downregulation of MHC class I expression during PC
progression
To verify the PCA findings, we analyzed the expression
levels of genes involved in MHC class I antigen processinginfiltration of CD68+ immune cells and (B) borderline higher infiltration
 castration-resistant prostate cancer bone metastases. Sections show
mple.
astration-resistant Prostate Cancer Bone Metastases Deﬁned
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Table 2 – Canonical pathways predicted by Ingenuity pathway analysis to be upregulated or downmodulated in AR-driven compared to non-
AR-driven castration-resistant prostate cancer bone metastases according to whole-genome array analysis and principal component analysis
Ingenuity canonical
pathway
p value a Ratio Category Molecules
Upregulated
Cholesterol biosynthesis
superpathway
0.004 0.26 Sterol biosynthesis DHCR7, ACAT2, MSMO1, HMGCS2, HMGCR,
TM7SF2, SC5D
Methionine degradation
superpathway
0.005 0.23 Methionine degradation CBS/CBSL, DLD, PCCB, CTH, MUT, SUOX, AHCY
Fatty acid b-oxidation I 0.025 0.20 Fatty acid degradation ACSL3, SLC27A2, ECI2, AUH, IVD, HSD17B4
2-Oxobutanoate degradation I 0.025 0.60 2-Oxobutanoate degradation DLD, PCCB, MUT
Cholesterol biosynthesis 0.025 0.31 Sterol biosynthesis DHCR7, MSMO1, TM7SF2, SC5D
Pyrimidine ribonucleotide
interconversion
0.032 0.19 Pyrimidine nucleotide biosynthesis NME3, NME4, ENTPD6, AK4, CANT1
b-Alanine degradation I 0.032 1.0 B-Alanine degradation ABAT, ALDH6A1
Spermine biosynthesis 0.032 1.0 Amine and polyamine biosynthesis SMS, AMD1
Cysteine biosynthesis/
homocysteine degradation
0.032 1.0 Homocysteine degradation,
cysteine biosynthesis
CBS/CBSL, CTH
Pyrimidine ribonucleotide de
novo biosynthesis
0.042 0.18 Pyrimidine nucleotide de novo
biosynthesis
NME3, NME4, ENTPD6, AK4, CANT1
Downregulated
Hepatic ﬁbrosis / hepatic stellate
cell activation
2e-08 0.18 Disease-speciﬁc pathways;
ingenuity toxicity list pathways
IGFBP4, FN1, MYH9, SMAD3, KLF6, COL8A1, CCL5,
PDGFC, COL15A1, COL5A1, IL1R2, COL1A2, TIMP1,
PDGFRA, COL22A1, COL18A1, KLF12, TNFRSF1B,
TIMP2, PDGFRB, TNFRSF11B, VCAM1, COL5A2,
MMP2, IFNAR2, COL1A1, TLR4, LY96, COL6A3,
CD40, IL10RA, CD14
Antigen presentation pathway 7e-08 0.38 Cellular immune response; humoral
immune response
HLA-G, B2M, PSMB9, HLA-DRB4, HLA-DRB1, HLA-
DMA, HLA-A, HLA-B, CD74, PSMB8, HLA-F, TAPBP,
HLA-E, MR1
Leukocyte extravasation signaling 1e-07 0.16 Cellular immune response RAC2, CLDN11, MMP16, TIMP1, CYBA, CYBB,
RASSF5, ACTN1, ACTA1, TIMP2, VCAM1, CXCR4,
ACTB, ARHGAP4, ITGA5, THY1, MMP2, NCF4,
GNAI2, BTK, ITGB2, WIPF1, ITGAM, ARHGAP9,
WAS, JAM3, PLCG2, PIK3CD, ACTN4, PRKCB, MSN
Caveolar-mediated Endocytosis
Signaling
1E-06 0.24 Cellular Immune Response;
Organismal Growth and
Development; Pathogen-Inﬂuenced
Signaling
B2M, FYN, HLA-A, ACTB, HLA-B, CD48, ITGA5,
ITGB7, ITGB2, ITGAM, FLNC, ITGA11, ITGA9, CAV1,
ITGB4, ACTA1, ITGAX
Crosstalk between Dendritic Cells
and Natural Killer Cells
1E-06 0.21 Cellular Immune Response TYROBP, HLA-A, ACTB, CD69, HLA-B, LTB, HLA-G,
TLR4, PRF1, HLA-DRB1, HLA-DRB4, MICB, CD40,
FSCN1, CD86, TNFRSF1B, HLA-F, ACTA1, HLA-E
Allograft rejection signaling 1e-06 0.29 Cellular immune response;
disease-speciﬁc pathways
HLA-G, B2M, PRF1, HLA-DRB4, HLA-DRB1, CD40,
HLA-DMA, GZMB, HLA-A, HLA-B, FCER1G, CD86,
HLA-F, HLA-E
Complement system 2e-06 0.33 Humoral immune response C1R, ITGB2, CFD, ITGAM, C5AR1, CFB, CFI, C1QC,
C1QA, C1QB, C2, ITGAX
Dendritic cell maturation 3e-06 0.15 Cellular immune response;
cytokine signaling; pathogen-
inﬂuenced signaling
B2M, PLCB2, TYROBP, FCGR2A, HLA-A, HLA-B, LTB,
PLCL2, FCGR1A, COL1A2, COL1A1, TLR4, HLA-
DRB4, HLA-DRB1, CD40, HLA-DMA, DDR2, FSCN1,
PLCG2, FCER1G, CD86, PIK3CD, IRF8, COL18A1,
TNFRSF1B, TNFRSF11B
Integrin signaling 6e-06 0.14 Cell cycle regulation; cellular
growth, proliferation and
development; intracellular and
second messenger signaling
RAC2, RAP2A, FYN, MPRIP, TSPAN7, ARPC5, ITGB7,
RHOG, ITGA11, ITGA9, CAV1, ITGB4, TSPAN4,
ACTA1, ACTN1, ASAP1, ACTB, ITGA5, RHOJ, GSN,
ITGB2, WIPF1, ITGAM, WAS, PLCG2, PIK3CD,
ACTN4, ITGAX
Phagosome formation 7E-06 0.19 Cellular Immune Response;
Pathogen-Inﬂuenced Signaling
PLCB2, FN1, MRC2, FCGR2A, TLR8, ITGA5, RHOJ,
PLCL2, FCGR1A, INPP5D, TLR4, RHOG, SCARA3,
PLCG2, SYK, FCER1G, PIK3CD, MARCO, PRKCB
a P value after FDR correction according to Benjamini-Hochberg.
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set of CRPC bone metastasis samples (n = 53), non-treated
PC metastases (n = 11), and non-treated metastases from
other malignancies (n = 13; Fig. 3). Levels in metastases
were compared to levels in paired samples of non-
malignant and malignant prostate tissue from radical
prostatectomies (n = 12). PSMB9, TAP1, and HLA-A mRNAPlease cite this article in press as: Ylitalo EB, et al. Subgroups of 
Through an Inverse Relationship Between Androgen Receptor Acti
10.1016/j.eururo.2016.07.033levels in bone metastases were significantly lower in PC
patients than in patients with other malignancies (Fig. 3A–
C). However, and in accordance with the array data, the
CRPC bone metastases could be classified into two groups
on the basis of their variation in PSMB9, TAP1, and HLA-A
mRNA levels (Fig. 3D), suggesting MHC class I antigen
presentation was downregulated in the majority of CRPCCastration-resistant Prostate Cancer Bone Metastases Deﬁned
vity and Immune Response. Eur Urol (2016), http://dx.doi.org/
Fig. 3 – Relative mRNA levels of (A) PSMB9, (B) TAP1, and (C) HLA-A in paired nonmalignant and malignant prostate tissue samples from patients
treated with radical prostatectomy (n = 12) and in non-treated (n = 11) and castration-resistant prostate cancer (CRPC) bone metastases (n = 53) and
bone metastases from other malignancies (n = 13). * p < 0.05, ** p < 0.01, *** p < 0.001. (D) Principal component analysis of bone metastases samples
from CRPC patients (beige) and patients with other malignancies (orange). Score plot for the first principal component, for which each dot
corresponds to one patient sample. Samples cluster according to their relative PSMB9, TAP1, and HLA-A mRNA levels. met = metastases.
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Notably, PSMB9, TAP1, and HLA-A mRNA levels were all
significantly lower in malignant compared to nonmalignant
prostate tissue and were even lower in bone metastasis
tissue (Fig. 3A–C).
Accordingly, immunoreactivity for HLA class I ABC was
lower in metastases than in matched primary tumor
biopsies obtained at diagnosis (median 37 mo [IQR 16–79
mo] before metastasis surgery; p = 0.037, n = 29; data not
shown), indicating a reduction in MHC class I protein
expression during PC disease progression.
3.4. Inverse correlation between MHC class I expression and
nuclear AR immunoreactivity in CRPC metastases
The PCA model indicated downregulated MHC class I
antigen presentation in AR-driven CRPC bone metastases
compared to preservation of MHC class I antigen presenta-
tion in non–AR-driven CRPC bone metastases, so we studied
HLA class I ABC immunoreactivity in relation to nuclear AR
immunoreactivity (previously measured in those metasta-
ses and assumed to reflect AR activity [6]). HLA class I ABC
immunoreactivity in tumor cells was evaluated in metasta-
ses for which FFPE tissue was available, and was found to bePlease cite this article in press as: Ylitalo EB, et al. Subgroups of C
Through an Inverse Relationship Between Androgen Receptor Acti
10.1016/j.eururo.2016.07.033inversely correlated to the nuclear AR score (Rs = 0.49,
p = 0.001, n = 41; Fig. 4 A–D). Importantly, metastases with
moderate to intense HLA class I ABC immunoreactivity
showed a significantly higher frequency of CD3+ infiltrating
cells than cases with negative to weak immunostaining
(Supplementary Fig. 3).
Staining heterogeneity was observed for both AR and
HLA class I ABC immunoreactivity in many cases, so double
staining was performed. Nuclear AR showed a clear inverse
staining pattern to HLA class I ABC (Fig. 4E). FOXA1 staining
in consecutive sections indicated reduced but not complete-
ly diminished FOXA1 levels in AR-negative/HLA class I ABC–
positive tumor cells (Fig. 4F).
3.5. Reduced expression of HLA class I ABC in primary prostate
tumors with advanced disease stage
To evaluate if MHC class I expression in primary PC is
related to patient prognosis, HLA class I ABC immunoreac-
tivity was evaluated in a TMA including transurethral
cancer biopsies from 284 patients with long clinical follow-
up and in adjacent benign tissue in 179 cases. Malignant
epithelial cells showed less intense staining than adjacent
benign epithelial cells (p < 0.0001; Fig. 5A). Lower HLA ABCastration-resistant Prostate Cancer Bone Metastases Deﬁned
vity and Immune Response. Eur Urol (2016), http://dx.doi.org/
Fig. 4 – Immunohistochemistry for (A,B) HLA class I ABC and (C,D) androgen receptor (AR) in bone metastasis tissue sections from patients with
castration-resistant prostate cancer (CRPC). One patient exhibits negative HLA class I staining (A) and intense nuclear AR staining (C) while the other
exhibits intense HLA class I staining (B) and negative nuclear AR staining. (E) Double staining for HLA class I ABC (red) and AR (brown) in CRPC
metastasis and (F) immunohistochemistry for FOXA1 in a parallel metastasis section. Magnification according to scale bars in the figure.
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the presence of metastases at diagnosis (Supplementary
Table 1). In addition, when patients with metastases (M1)
at diagnosis were excluded from the analysis, patients with
low (negative to weak) HLA ABC immunoreactivity had
shorter cancer-specific survival than patients with moder-
ate to intense immunoreactivity (Fig. 5B; p = 0.047,
n = 248). In patients managed with watchful waiting
(n = 202), a similar but nonsignificant trend was seen
(Fig. 5C; p = 0.13).
4. Discussion
We found two subgroups among CRPC bone metastases,
defined by high AR activity and low cellular immune
responses, or low AR activity and high cellular immunePlease cite this article in press as: Ylitalo EB, et al. Subgroups of 
Through an Inverse Relationship Between Androgen Receptor Acti
10.1016/j.eururo.2016.07.033responses. Moreover, CRPC bone metastases with high AR
activity seemed to have higher metabolic activities than
metastases with low AR activity. To the best of our
knowledge, these two CRPC subgroups have not previously
been described. Our results confirm previous findings of
lower levels of PSMB9, TAP1, and HLA class 1 molecules in
PC compared to benign prostate tissue [9–11]. Importantly,
we also present novel data indicating an association
between low tumor HLA class I ABC immunoreactivity at
diagnosis and poor clinical outcome, as well as markedly
lower HLA class I expression in PC bone metastases
compared to primary tumors.
The subgroups observed had similar expression levels
of neuroendocrine and cancer stem-cell markers
(Supplementary Table 2), and we found no enrichment of
tumors negative for MHC class I among docetaxel-treatedCastration-resistant Prostate Cancer Bone Metastases Deﬁned
vity and Immune Response. Eur Urol (2016), http://dx.doi.org/
Fig. 5 – Tumor immunoreactivity for HLA class I ABC in a historical cohort of patients diagnosed via transurethral section of the prostate showing (A)
reduced staining intensity in malignant (n = 284) compared to adjacent nonmalignant (n = 179) epithelium (p < 0.001) and shorter cancer-specific
survival in patients with lower HLA class I tumor cell immunoreactivity (negative to weak) compared to patients with moderate to intense
immunoreactivity in (B) patients without metastases at diagnosis (p = 0.047, n = 248), and (C) patients treated with watchful waiting (p = 0.13, n = 202).
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EURURO-6937; No. of Pages 12patients, as previously reported [12]. Not surprisingly,
however, AR-V7 mRNA levels were much higher in the AR-
driven than in non–AR-driven CRPC metastases, while no
differences in AKR1C3 mRNA levels were seen (data not
shown and Supplementary Table 2). In addition to AR-
targeted therapies, we hypothesize that patients with AR-
driven CRPC metastases might benefit from therapies
targeting cholesterol biosynthesis, b-oxidation, andPlease cite this article in press as: Ylitalo EB, et al. Subgroups of C
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10.1016/j.eururo.2016.07.033polyamine synthesis, pathways that were particularly
upregulated in this subgroup. This is in line with previous
findings by our group of high cholesterol levels and b-
oxidation in CRPC bone metastases [13,14]. Furthermore,
we hypothesize that patients with non–AR-driven CRPC
metastases with preserved MHC class I expression will be
resistant to all forms of anti-AR therapy, but might instead
be susceptible to cancer immunotherapy.astration-resistant Prostate Cancer Bone Metastases Deﬁned
vity and Immune Response. Eur Urol (2016), http://dx.doi.org/
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cells are immunogenic, and the aim of immunotherapy is to
strengthen the endogenous antitumor response via immu-
nologic interventions [15]. Tumors develop in an immune-
suppressed environment in which cytotoxic CD8+ T cells
and NK cells are repressed by inhibitory factors expressed
by tumor cells, Tregs, and MDSCs, and in which MDSCs and
type M2 macrophages instead promote tumor growth via
secretion of factors that stimulate angiogenesis and tumor
cell invasion [15,16]. Most cancer immunotherapies are
developed to strengthen cytotoxic T and NK cell activity via
tumor vaccination or to inhibit immune checkpoint path-
ways such as the CTLA-4 or PDCD1/PD-L1 pathways [15].
Very little is known about the immune cell profile in PC
metastases. In primary PC, low tumor infiltration of T cells,
B cells, and monocytes has been observed in advanced
disease and associated with poor prognosis [17], although
recent studies highlight tumor infiltration of specific
lymphocyte/monocyte subtypes, such as FoxP3+ Tregs,
CD163+ M2 macrophages, and S100A9-positive inflamma-
tory cells, in lethal PC [18–22]. High blood fractions of Tregs
and MDSC have been related to poor prognosis in patients
with CRPC [23], as have a whole-blood–based mRNA profile
mirroring high monocyte/low lymphocyte numbers
[24]. Overall, this points to the rationale for using
immunotherapy for treatment of PC. Immunotherapies
that are being tested in the clinic for treatment of PC include
sipuleucel-T (dendritic cell–based vaccine using prostatic
acid phosphatase as antigen), Prostvac (viral-based vaccine
using PSA as antigen), GVAX (whole-cell–based vaccine),
tasquinimod (inhibitor of S100A9 and MDSC), and immune
checkpoint inhibitors such as ipilimumab (inhibitor of
CTLA-4) and pembrolizumab (inhibitor of PD-1)
[25]. Results from the present study highlight heterogene-
ities among CRPC bone metastases that might be important
to consider when choosing immunotherapy for individual
PC patients. For instance, the inverse correlation between
expression of MHC class I and AR-regulated genes probably
diminishes response to antigen-directed vaccines targeting
AR-stimulated genes (ACPP and PSA) in the majority of CRPC
cases with high AR activity (Supplementary Figure 4).
Instead, the high MHC class I expression, immune cell
infiltration, and levels of CTLA4, PDCD1, and S100A9
observed in non–AR-driven metastases suggest testing of
immune checkpoint inhibitors and Tasquinimod specifical-
ly in this subgroup of patients. However, the current study
includes a limited number of clinical CRPC bone metastases,
so the subgroup of 20% non–AR-driven cases is particularly
small. The results need to be verified in larger cohorts,
preferably including patients in trials for evaluation of
immune-strengthening therapies. Therapy-predicting mar-
kers in addition to low serum PSA levels could be MHC class
I expression in tumor cells and the immune cell profile in
metastasis tissue and blood. In patients with multimeta-
static disease, several metastases should be studied for
optimal information.
The molecular drivers behind the subgroups of CRPC
bone metastases observed are not known and need to
be examined further. We observed high levels of the ARPlease cite this article in press as: Ylitalo EB, et al. Subgroups of 
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10.1016/j.eururo.2016.07.033co-regulators FOXA1 and HOXB13, which might be
responsible for programming the AR cistrome in AR-driven
bone metastases [26], while the function of the prostate-
derived Ets factor SPDEF in PC is more controversial
[27,28]. The low immune-cell infiltration observed in AR-
driven metastases might be explained in part by low levels
of LYVE1 (Supplementary Table 4) and thus low predicted
numbers of lymphatic vessels, recently demonstrated as a
critical determinant of the metastatic process in colorectal
cancer through reduced immune cytotoxicity [29].
Low levels of the monocyte/lymphocyte chemoattractant
CCL5 and predicted low levels of pro-inflammatory
cytokines such as IFNG, TNF, CSF2, NFKB, and IL4
could obviously contribute as well. In non–AR-driven
metastases, the predicted activity of TGFb1, IL5, and other
anti-inflammatory factors might inhibit T-cell activity,
possibly via activation of Tregs and MDSC as discussed
above (Supplementary Table 4). The reduced expression of
MHC class I antigen–processing molecules in clinical PC
might be caused by structural defects, or possibly by
epigenetic, transcriptional, or post-transcriptional regula-
tion [30]. If so, there might be a possibility of restoring MHC
class I expression with IFNG or drugs inhibiting methyl-
ation or histone deacetylation [11,31,32]. The inverse
correlation observed between MHC class I expression and
AR activity is in line with previous results showing
increased lymphocyte density in human prostate after
ADT [33,34] and with the general effects of androgens in
suppressing both adaptive and innate immune responses
[35]. Taken together, these findings support the rationale
for treating PC patients with combinations  of ADT and
immunotherapy [36].
5. Conclusions
In conclusion, the majority of CRPC bone metastases show
high AR activity, high metabolic activity, low MHC class I
expression and low numbers of infiltrating immune cells. By
contrast, a subgroup of metastases shows low AR and
metabolic activity, but high MHC class I expression and
immune cell infiltration. Targeted therapies for these two
CRPC subgroups should be explored.
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